Pharmacological Mechanisms of Naltrexone and Acamprosate in the Prevention of Relapse in Alcohol Dependence
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Naltrexone and acamprosate may ultimately prove to be useful additions to pharmacotherapy for alcoholism by reducing relapse. Naltrexone is a relatively selective competitive antagonist at mu‐opioid receptors, and this activity may explain its anti‐relapse action either because endogenous opioids are involved in the positively reinforcing effects of alcohol and/or because these same transmitters are involved in the conditioned anticipation of these effects. In contrast, the pharmacology of acamprosate is still poorly understood. This is not surprising because it is a small flexible molecule with similarities to several neuro‐active amino acids and is used in high doses. All these factors suggest that it may have multiple actions. Currently, the best explanation for the effects of acamprosate seems to be that it inhibits the glutamatergic transmitter system involved in both the negative reinforcing effects of alcohol and the conditioned “pseudo‐withdrawal” that may be important in cue‐induced relapse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alteration of ethanol self-administration by naltrexone
Altshuler, H. L., Phillips, P. E., & Feinhandler, D. A. (1980) · Life Sciences · doi:10.1016/0024-3205(80)90257-x · Cited by 397
Heyser, C. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00130-9 · Cited by 176
Dahchour, A., De Witte, P., Bolo, N., Nédélec, J.-F., Muzet, M., Durbin, P., & Macher, J.-P. (1998) · Psychiatry Research: Neuroimaging · doi:10.1016/s0925-4927(98)00016-x · Cited by 165
Le Magnen, J., Tran, G., Durlach, J., & Martin, C. (1987) · Alcohol · doi:10.1016/0741-8329(87)90005-x · Cited by 97
Cole, J. C., Littleton, J. M., & Little, H. J. (2000) · Psychopharmacology · doi:10.1007/s002130050009 · Cited by 65
Self-citation
Cited by
Anton, R. F., O’Malley, S. S., Ciraulo, D. A., Cisler, R. A., Couper, D., Donovan, D. M., Gastfriend, D. R., Hosking, J. D., Johnson, B. A., LoCastro, J. S., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2003 · Cited by 1,930
Is there a common molecular pathway for addiction?
Nestler, E. J. (2005) · Nature Neuroscience · doi:10.1038/nn1578 · Cited by 1,388
“Acamprosate, which may act by reducing NMDA glutamatergic receptor function (although this remains speculative), is reported to be effective for some alcohol addict”
BackgroundGarbutt, J. C., Kranzler, H. R., O’Malley, S. S., Gastfriend, D. R., Pettinati, H. M., Silverman, B. L., Loewy, J. W., Ehrich, E. W., & Vivitrex Study Group, F. T. (2005) · JAMA · doi:10.1001/jama.293.13.1617 · Cited by 635
Volkow, N. D., & Blanco, C. (2023) · World psychiatry · doi:10.1002/wps.21073 · Cited by 503
Acamprosate for alcohol dependence
Rösner, S., Hackl-Herrwerth, A., Leucht, S., Lehert, P., Vecchi, S., & Soyka, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004332.pub2 · Cited by 412
Metadata
- Authors
- Littleton, J., & Zieglgänsberger, W.
- Venue
- The American Journal on Addictions
- Publisher
- Wiley
- Published
- 2003-05-06
- Volume
- 12
- Issue
- s1
- Pages
- s3-s11
- ISSN
- 1055-0496 (ISSN-L)
- 1521-0391
- OpenAlex
- W2064255404
- Cited by
- 110
- References
- 5
- FWCI
- 6.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological Mechanisms of Naltrexone and Acamprosate in the Prevention of Relapse in Alcohol Dependence. https://app.cochat.ai/papers/10.1111/j.1521-0391.2003.tb00492.x
- The paper
- Littleton, J., & Zieglgänsberger, W. (2003). Pharmacological Mechanisms of Naltrexone and Acamprosate in the Prevention of Relapse in Alcohol Dependence. The American Journal on Addictions. https://doi.org/10.1111/j.1521-0391.2003.tb00492.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.